How Garadacimab Might Be a Better Option for Hereditary Angioedema Patients

Introduction

Hereditary angioedema (HAE) is a rare condition characterized by painful swelling. Two treatments, garadacimab and lanadelumab, were evaluated to determine which is more effective.

Study Design

• Garadacimab: Administered once a month.
• Lanadelumab: Administered either every two weeks or every four weeks.
• Method: Researchers used matching-adjusted indirect comparison (MAIC) due to the lack of direct comparisons.

Key Metrics Evaluated

1. Frequency of HAE attacks
2. Attacks requiring additional treatment
3. Moderate or severe attacks
4. Attack-free patients
5. Quality of life improvements

Results

Garadacimab vs. Lanadelumab (Every Two Weeks)

• Significant reduction in moderate and severe attacks.
• Improved quality of life.

Garadacimab vs. Lanadelumab (Every Four Weeks)

• Fewer attacks
• Fewer attacks needing extra treatment
• Fewer moderate or severe attacks
• More attack-free patients
• Better quality of life

Conclusion

• Garadacimab shows potential as a better long-term treatment option for HAE.
• Note: This is an indirect comparison; direct head-to-head trials are needed to confirm findings.